Smart Money Is Racing Into The Biotech Boom

FN Media Group Presents Market Commentary


New York, NY – May 8, 2020 – The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs.  Mentioned in today’s commentary includes:  CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO),  Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).


From exciting new technology to the FDA’s ‘fast-tracking’ of brand new therapies for a wide range of treatments, the biotech industry has once again found itself at exactly the right place at exactly the right time.


Before investing, however, it’s essential to know every detail about a company – and their particular niche. Not only is the industry notorious for small companies exploding and then promptly losing it all, but it’s also on the cusp of brand new and potentially major breakthroughs, meaning that without the proper government green lights, even the most brilliant projects could be shut down in the blink of an eye.  And with the industry growing faster than ever, it’s never been more important to stay ahead of these trends and regulations.


From industry giants like Microsoft to breakout start-ups like Champignon Brands (SHRM; SHRMF) – the next great quantum physics or biotech boom is all about positioning yourself. That’s why we’ve put together an outline of everything you need to know about one of the most exciting trends in the biotech sector as it expands in 2020.


An All Natural Solution

The secret to a successful biotech story lies in one thing: innovation. Really making a dent in this market isn’t as easy as simply repacking an old idea, it’s about seeing a solution for a problem no one else seems to be able to solve.


See, the world is experiencing a sort of mental health crisis. We’ve grown further apart than ever thanks to television, cellphones, and the internet. And we’ve lost touch with a lot of the things that used to bring us together.


As a result, mental health has become a global emergency. And while traditional psychiatric medications are able to help most people. Many people are still struggling.


For years, ‘fringe’ doctors and psychonauts have praised the benefits of a certain type of drug. In fact, these all-natural therapies go back for centuries.


Now, with the beginning of a wave of decriminalization taking place across the United States, psychedelics are targeting the center of a $13 billion medical boom. And one little-known company called Champignon Brands (SHRM; SHRMF) saw this trend coming and its stock has already tripled in value since January. And that’s because they’ve got lots going for them.


First, they’ve got a vision. To bring help to a population who haven’t been able to benefit from Big Pharma’s traditional medicines. They have a whole range of compounds that in clinical trials help everything from depression and anxiety to PTSD and alcoholism.


While these highly praised medicines are still considered illegal, they’re starting to benefit from a new wave of acceptance across the United States and the globe. The FDA just fast-tracked psilocybin, MDMA and ketamine for therapeutic research.  And the results in tests so far have been astounding.


Champignon Brands (SHRM; SHRMF) saw this coming, in fact. That’s why they’ve been strategically positioning themselves for the next big biotech boom.


Unlike many companies in the biotech space, where investors expose themselves to massive risk in the hopes that a certain medical trial will pay off, Champignon Brands has an integrated vertical business model that provides it with a steady income to fund its groundbreaking medical trials.


Additionally, Champignon Brands (SHRM; SHRMF) has an impressive acquisition list, buying up key companies in the industry in its determination to dominate this up and coming trend.


The Great CRISPR Debate


CRISPR is the technology at the center of one of the biggest debates in the scientific world. And it’s also one of the most fast-moving technologies in the scientific world. Imagine how quickly computers went from giant boxes that took up entire rooms to little rectangles that fit in your pocket. Now think about how that progression has impacted modern life.


A similar development is being worked on right now with CRISPR technology, a simple yet extremely powerful tool for editing genomes. Gene-editing has unlocked a whole world of medical possibilities, like treating cancer or HIV.


These are what are called therapeutic-somatic genetic modifications. But it’s slightly more complicated than that.  It also introduces the possibility of removing the genes that would essentially make a baby immune to those same diseases from the get-go.  And while that’s already quite controversial, the debate really picks up when you consider the same technology could be used to make your future child taller, smarter, prettier or wittier.


It’s essentially pandora’s box – and science has just opened it. But there are some companies pursuing the technology responsibly.


Take CRISPR Therapeutics (NASDAQ:CRSP), for instance. Their research focuses entirely on the development of transformative gene-based medicine.  Their treatments adhere to the current recommendations of the International Society for Stem Cell Research and target only somatic cells, which means their treatments will not be able to be transferred to a patient’s child.


Sangamo Therapeutics (NASDAQ:SGMO) is another diverse biotech player with a lot of promising treatments in its pipeline.


From treatments for Huntington’s disease to Hemophilia, Sangamo is developing capabilities that allow them to design therapeutic approaches to resolve the underlying genetic causes of disease.


Quantum Computers


Quantum computing is going to transform the world as we know it. From curing cancer to bringing an end to climate change, this is where the world’s biggest questions are being answered.


Problems that we have previously considered ‘impossible’ could soon be solved in the click of a button. And breakthroughs are being made every day.


Microsoft’s (MSFT) Quantum Lab in Sydney, Australia is a prime example. It has developed the ability to control 50,000 qubits through three wires, a cryogenic CMOS design, and a 1cm2 chip computing at near absolute zero temperatures.


In the words of the director of the Quantum Lab, it is “one of the most sophisticated micro-devices ever made” and its ability to work with any type of quantum computing hardware could change the entire industry.


The next step for Microsoft now that they have this chip is to scale up the computer and begin solving real-world problems.


Arguably the most exciting problem out there is ending climate change. The idea, just like with Google’s hydrogen simulation, is to simulate large complex molecules and then uncover new catalysts for carbon capture that are cheap and hyper-efficient.


Currently, we can simulate small molecules up to a few dozen qubits but need to scale this to the order of 1 million to solve these kinds of problems. Either of these computing giants could hold the key to the next great breakthrough – changing the world forever.


IBM (IBM) is another tech giant with its feet in the healthcare pool. Not only has it leveraged its big data edge to enhance and provide insights into traditional healthcare platforms, it is also on the cutting edge of machine learning and artificial intelligence innovation.


One such service it provides is a platform for health insurance companies to better manage their customer service through the use of conversational artificial intelligence. Customers can expect quick responses and precise answers to many questions relating to their healthcare plan and more.


Another breakthrough is IBM’s Geisinger Health System. This system leverages machine learning to gain insights into the tremendous amount of data health care providers gather, helping researchers gain more knowledge, and in turn, create new and exciting treatments that are sure to help treat the world’s biggest illnesses.


Even the iconic Apple (AAPL) is driving innovation in healthcare. And in a unique way that many wouldn’t expect. Its wearable technology, and the data it captures, has opened up a tremendous array of new insights into the world of healthcare.


Not only is its data actively helping save lives, its products are as well. In fact, the iWatch even comes equipped with an innovative feature called Fall Detection. The technology will detect significant – and potentially dangerous – falls, and automatically call emergency services if you have been immobile for a set amount of time. Additionally, the watch will even send a message to your emergency contacts to let them know that emergency services have been notified.


By Charles Kennedy




FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include: that governments will legalize and regulate psychedelic medicine; that the worldwide functional mushroom markets combined will be worth $34.3 billion in gross sales in 2024; that Champignon Brands Inc. (“Champignon”) can build an on-site research laboratory within the next 12-24 months; and rollout five additional clinics in the US by the end of 2020; can access the expertise of Champignon’s acquisition targets’ management teams to create and market depression and anxiety treatments; and that Champignon’s business will be profitable. Forward-looking information is based on the opinions and estimates of Champignon at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information.  Psychedelic medicine may not be legalized on the timeline as expected or at all; psychedelic medicine may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; Champignon may not be able to close on its announced acquisitions because of regulatory approval requirements or other reasons; that the acquisitions do not provide the expected benefits, business or expertise expected; that Champignon may not be as able to diversify or scale up  as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements or lack of suitable employees, partners or suppliers; none of Champignon’s treatments have passed clinical trials or received FDA or other health authorities’ approval; Champignon may not be able to raise funds and develop better treatments than competitors in the psychedelic medicine industry; actual operating performance of the facilities Champignon do not meet expectations; that competition quickly develops; that Champignon may not be able to retain key employees, partners and suppliers; costs may be higher than expected and profits therefore lower; and other risks affecting the Company in particular and the psychedelic medicine industry generally, including without limitation risks related to most agricultural crops, including crop failure and medical developments, including without limitation failure of human trials or rejection by medical regulators. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.




PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities., Joint Salty Holdings Corp., and their owners, managers, employees, and assigns (collectively, “we” or the “Company”) has been paid by the profiled company to disseminate this communication. In this case the Company has been paid by Champignon seven thousand US dollars per month for market awareness including postings and articles. This compensation is a major conflict with our ability to be unbiased, more specifically:


This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Champignon to conduct investor awareness advertising and marketing for [SHRM.V and SHRMTF.PK]. receives financial compensation to promote public companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of SHRM. The profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.


We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.


SHARE OWNERSHIP. The owner of owns shares of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The owner of will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.


NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.


LEGAL ADVISORY. Investing in companies associated with the psychedelic medicine industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the psychedelic medicine industry, potential investors should check with their legal advisor as to whether an investment will breach local or federal law.


RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.


DISCLAIMER: (FMP) is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.




This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact e-mail:  U.S. Phone: +1(954)345-0611